Emergent BioSolutions (EBS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Definitive additional proxy materials were filed in connection with the upcoming annual meeting scheduled for April 29, 2026.
The annual meeting will be held virtually, allowing shareholders to participate online.
Voting matters and shareholder proposals
Shareholders are invited to attend and vote at the virtual annual meeting on April 29, 2026.
Shareholder rights and capital structure
No filing fee was required for this proxy material submission, indicating routine annual meeting matters.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Emergent BioSolutions
- Q1 2026 revenue beat guidance but fell 30% YoY; liquidity and outlook remain strong.EBS
Q1 20261 May 2026 - Strong financial turnaround, all proposals approved, and growth-focused strategies outlined.EBSAGM 202629 Apr 2026
- Annual meeting on April 29, 2026, with proxy voting available for eligible shareholders.EBSProxy filing28 Apr 2026
- Approval is sought for a new equity plan to support ongoing turnaround and talent retention.EBSProxy filing23 Apr 2026
- Annual meeting on April 29, 2026; eligible shareholders urged to vote by proxy.EBSProxy filing16 Apr 2026
- Shareholders will vote on key proposals at the April 29, 2026, annual meeting.EBSProxy filing16 Apr 2026
- Proxy covers director elections, auditor ratification, pay, and equity plan amendment.EBSProxy filing20 Mar 2026
- Key votes include director elections, auditor ratification, and stock plan amendment.EBSProxy filing20 Mar 2026
- 2025 saw a profitable turnaround with $743M revenue, margin gains, and lower leverage.EBSQ4 202526 Feb 2026